Stifel Nicolaus Lowers Affimed (NASDAQ:AFMD) Price Target to $4.00

Affimed (NASDAQ:AFMD - Free Report) had its price objective decreased by Stifel Nicolaus from $5.00 to $4.00 in a report issued on Friday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company's stock.

A number of other research firms have also recently issued reports on AFMD. Cantor Fitzgerald reiterated an "overweight" rating on shares of Affimed in a research note on Monday, September 9th. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Affimed in a research note on Friday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Affimed Stock Down 4.7 %

Shares of AFMD stock traded down $0.17 during trading on Friday, hitting $3.48. 132,553 shares of the company were exchanged, compared to its average volume of 266,981. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. The business's 50-day simple moving average is $3.50 and its 200 day simple moving average is $4.54. Affimed has a twelve month low of $2.92 and a twelve month high of $8.95.

Affimed (NASDAQ:AFMD - Get Free Report) last posted its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.09). The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. On average, equities analysts forecast that Affimed will post -4.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Choreo LLC bought a new position in Affimed during the second quarter worth $54,000. Jane Street Group LLC bought a new stake in Affimed in the 3rd quarter valued at $44,000. FMR LLC increased its holdings in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC increased its holdings in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company's stock valued at $317,000 after buying an additional 10,250 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company's stock valued at $1,152,000 after buying an additional 15,108 shares during the period. Institutional investors own 30.82% of the company's stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.